Ocugen, Inc. filed a Form 8-K on September 22, 2026, reporting the outcome of its September 21, 2026 Special Meeting of Stockholders, at which a vote to increase authorized common shares was adjourned to October 5, 2026 to allow additional time for proxy solicitation.
Key Highlights
- Authorized shares proposal adjourned: A vote on adding 250,000,000 shares of common stock to Ocugen's authorized share count was deferred to October 5, 2026 at 8:00 a.m. Eastern Time.
- Quorum achieved: 160,214,431 shares, representing 47.3% of common stock outstanding as of the July 27, 2026 record date, were represented at the Special Meeting.
- Adjournment proposal approved: Stockholders approved adjourning the meeting with 124,584,658 votes in favor, 33,639,820 against, and 1,989,953 abstentions.
- Record date unchanged: July 27, 2026 remains the record date for the Adjourned Meeting on Proposal 1.
- No action required for prior voters: According to the filing, stockholders who already voted and do not wish to change their vote on Proposal 1 need not take any further action.
Ocugen Stockholders Defer Vote on Common Stock Authorization Increase
Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company incorporated in Delaware and headquartered in Malvern, Pennsylvania, convened a Special Meeting of Stockholders on September 21, 2026 to address two proposals. The first, designated Proposal 1, sought stockholder approval of an amendment to the company's Sixth Amended and Restated Certificate of Incorporation, as amended, that would increase the number of authorized shares of common stock, par value $0.01 per share, by 250,000,000 shares. The second proposal, Proposal 2, asked stockholders to approve an adjournment of the Special Meeting if insufficient votes had been cast to pass Proposal 1.
According to the filing, a quorum was present, with 160,214,431 shares, or 47.3% of the outstanding common stock as of the July 27, 2026 record date, represented virtually or by proxy. Proposal 2, the adjournment proposal, was approved, with 124,584,658 votes cast in favor, 33,639,820 votes against, and 1,989,953 abstentions. As a result, the Special Meeting was adjourned solely with respect to Proposal 1, and the Adjourned Meeting is scheduled for October 5, 2026 at 8:00 a.m. Eastern Time. The filing notes that the July 27, 2026 record date will continue to apply to the Adjourned Meeting. The 8-K was signed by Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.
What Was Disclosed
Ocugen's 8-K disclosed the vote tabulation from its September 21, 2026 Special Meeting, confirming that stockholders approved adjourning the meeting to October 5, 2026, in order to gather additional proxies for a proposed 250,000,000-share increase to authorized common stock.



Please wait processing your request...